Tesamorelin vs Sermorelin: GHRH Analogs Compared

Tesamorelin and sermorelin are both synthetic analogs of growth hormone-releasing hormone (GHRH) that bind to GHRH receptors and stimulate pituitary growth hormone (GH) secretion. While mechanistically similar, they differ substantially in pharmacokinetics, FDA approval pathways, and clinical applications.

Sermorelin (also called somatocrinin) was the first synthetic GHRH analog developed. It was FDA-approved in 1997 as Geotropin for diagnostic testing of GH deficiency and later for GH-deficient adults, though it was withdrawn from the US market in 2008. It remains available through compounding pharmacies.

Tesamorelin (also called TX-GAT or TH9507) is a second-generation GHRH analog developed by ConjuChem. It received FDA approval in 2010 for HIV-associated lipodystrophy and is the only GHRH agonist with current FDA approval. The key difference lies in its chemical modification: the addition of a trans-3-hexenoic acid moiety extends its half-life and increases receptor binding affinity compared to native GHRH or sermorelin.

Both are used off-label for anti-aging and performance enhancement, though neither is FDA-approved for those indications.

Sermorelin pharmacokinetics:

- Half-life: 7-15 minutes (very short) - Onset: Rapid; GH response within 15-30 minutes - Peak GH: Achieved at 30-60 minutes - Dosing schedule: Typically 0.5-1 mg subcutaneously once or twice daily (evening preferred) - Duration of action: 2-4 hours of elevated GH - Result: Pulsatile, physiologic GH pattern

Tesamorelin pharmacokinetics:

- Half-life: 26-38 minutes (2.5-3x longer than sermorelin) - Onset: Slightly delayed; GH response begins at 20-40 minutes - Peak GH: Achieved at 40-90 minutes - Dosing schedule: Typically 2 mg subcutaneously once daily (evening) - Duration of action: 3-5 hours of elevated GH - Result: More sustained GH elevation with maintained pulsatility

The extended half-life of tesamorelin allows once-daily dosing compared to sermorelin's requirement for multiple daily injections. This translates to better patient adherence and reduced injection burden.

Sermorelin clinical evidence:

- FDA approval: Yes (Geotropin, 1997); now only via compounding pharmacies - FDA-approved indication: GH deficiency diagnosis and treatment (withdrawn from commercial market in 2008) - Published human trials: 25+ published studies, including: - GH deficiency replacement in adults - Multiple double-blind, placebo-controlled trials (Phase 2-3) - Long-term safety data spanning 10+ years - Evidence quality: Substantial; FDA-approved with robust clinical documentation - Use in lipodystrophy: Limited evidence; off-label use only

Tesamorelin clinical evidence:

- FDA approval: Yes (Egrifta, 2010) - FDA-approved indication: HIV-associated lipodystrophy (visceral fat reduction) - Published human trials: 15+ published studies, including: - Phase 2b/3 trials for HIV lipodystrophy (primary indication) - Visceral adipose tissue reduction (primary endpoint) - Metabolic effects secondary to lipodystrophy reversal - Evidence quality: Substantial but narrower in scope; FDA approval for specific indication - Clinical outcomes: 20-30% reduction in visceral adiposity in HIV patients - Use in anti-aging: Very limited evidence; off-label

The key difference: sermorelin has broader clinical evidence (GH deficiency across populations), while tesamorelin has FDA approval but for a narrower indication (HIV lipodystrophy).

Sermorelin mechanism:

- Structure: 29-amino acid synthetic GHRH (identical to natural GHRH 1-29) - Receptor binding: Moderate affinity for GHRH receptors on pituitary somatotrophs - Duration at receptor: Brief; rapidly cleared from circulation - GH response: Dose-dependent; 0.5-1 mg typically elevates GH 2-5x above baseline - Endogenous GH axis: Stimulates physiologic pulsatile GH secretion; no suppression of endogenous GHRH

Tesamorelin mechanism:

- Structure: Sermorelin analog with trans-3-hexenoic acid conjugation at the N-terminus - Receptor binding: Higher affinity for GHRH receptors; the hexenoic acid modification enhances binding and extends half-life - Duration at receptor: Extended; the modification protects from enzymatic degradation - GH response: Similar dose-response to sermorelin per unit, but sustained longer; 2 mg typically elevates GH 3-6x above baseline - Endogenous GH axis: Stimulates physiologic GH secretion; no suppression of endogenous GHRH

Comparative efficacy:

The trans-3-hexenoic acid modification is the critical difference. This chemical addition: - Increases stability in circulation (longer half-life) - Enhances receptor binding affinity (more potent at lower doses) - Extends duration of action (sustained GH elevation)

In clinical trials, tesamorelin produced more durable visceral fat reduction in HIV lipodystrophy, suggesting superior sustained GH action. However, sermorelin's pulsatile pattern may better mimic physiologic GH secretion for anti-aging applications.

Choose Sermorelin if:

- You prioritize evidence for GH deficiency treatment (FDA-approved for this indication) - You want most physiologic pulsatile GH pattern (multiple daily injections mimic natural secretion) - You accept frequent dosing (1-2 times daily) in exchange for better physiologic rhythm - You want the longest clinical safety record (25+ years of published data) - Cost is critical (sermorelin is generally cheaper through compounding pharmacies)

Choose Tesamorelin if:

- You want FDA-approved status with current market availability (Egrifta) - You prioritize convenience (once-daily dosing vs 1-2 times daily) - You have visceral fat accumulation (only GHRH analog with FDA approval for lipodystrophy) - You prefer longer half-life and more sustained GH elevation - You accept slightly higher cost (Egrifta is expensive on insurance; compounded tesamorelin varies)

Direct comparison:

| Feature | Sermorelin | Tesamorelin | |---------|-----------|------------| | FDA-approved | Yes (withdrawn) | Yes (current) | | Half-life | 7-15 min | 26-38 min | | Dosing frequency | 1-2x daily | Once daily | | Clinical evidence | Extensive (GH deficiency) | Moderate (HIV lipodystrophy) | | Visceral fat data | Limited | Robust (FDA indication) | | Anti-aging evidence | Very limited | Very limited | | Cost | $150-300/month | $300-600/month (compounded) | | Physiologic GH pattern | Better (pulsatile) | Good (sustained) |

Bottom line:

Both are effective GHRH agonists with solid evidence. Sermorelin is superior if you prioritize physiologic GH secretion and have been using it successfully. Tesamorelin is preferable if convenience matters and you have visceral fat accumulation or want FDA-approved status. For anti-aging use, the evidence gap between them is minimal; either is reasonable off-label, with sermorelin favored for cost and pulsatile physiology.